<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-sub-section" /><meta name="keywords" content="Sex hormones: progestogens; Progestogens: menstrual disorders; Progesterone; Dydrogesterone: menstrual disorders; Medroxyprogesterone: menstrual disorders; Norgestrel; Endometriosis; Menorrhagia; Premenstrual syndrome; Abortion: habitual see Miscarriage, recurrent; Miscarriage, recurrent; Hormone replacement: progestogens; Progestogens: HRT" /><meta name="IX" content="Sex hormones: progestogens; Progestogens: menstrual disorders; Progesterone; Dydrogesterone: menstrual disorders; Medroxyprogesterone: menstrual disorders; Norgestrel; Endometriosis; Menorrhagia; Premenstrual syndrome; Miscarriage, recurrent; Hormone replacement: progestogens; Progestogens: HRT" /><meta name="IXN" content="Abortion: habitual see Miscarriage, recurrent" /><title>6.4.1.2 Progestogens: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4336.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4336.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4336.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2073.htm">6 Endocrine system</a> &gt; <a href="4297.htm">6.4 Sex hormones</a> &gt; <a href="4298.htm">6.4.1 Female sex hormones</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="73961.htm" title="Previous: RALOXIFENE HYDROCHLORIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="201030.htm" title="Next: DYDROGESTERONE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4336">6.4.1.2 Progestogens</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i664.htm" title="Go to appendix 1">Progestogens</a>).</div><div><p>There are two main
groups of progestogen, progesterone and its analogues (<span>dydrogesterone</span> and medroxyprogesterone) and testosterone
analogues (<span>norethisterone</span> and norgestrel). The
newer progestogens (desogestrel, norgestimate, and gestodene) are
all derivatives of norgestrel; levonorgestrel is the active isomer
of norgestrel and has
twice its potency. <span>Progesterone</span> and its analogues
are less androgenic than the testosterone derivatives and neither <span>progesterone</span> nor <span>dydrogesterone</span> causes
virilisation.</p><p>Where endometriosis
requires drug treatment, it may respond to a progestogen, e.g. <span>norethisterone</span>, administered on a continuous basis. <span>Danazol</span> and <span>gonadorelin</span> analogues are
also available (<a title=" Drugs affecting gonadotrophins" href="4462.htm#_4462">section 6.7.2</a>).</p><p>Although oral progestogens have been used widely for menorrhagia they are relatively
ineffective compared with <span>tranexamic acid</span> (<a title=" Antifibrinolytic drugs and haemostatics" href="2824.htm#_2824">section 2.11</a>) or, particularly where dysmenorrhoea
is also a factor, <span>mefenamic acid</span> (<a title="monograph: MEFENAMIC ACID" href="5239.htm#_5239">section 10.1.1</a>); the levonorgestrel-releasing
intra-uterine system (<a title=" Intra-uterine progestogen-only contraceptive" href="31947.htm#_31947">section 7.3.2.3</a>) may
be particularly useful for women also requiring contraception. Oral
progestogens have also been used for severe dysmenorrhoea, but where
contraception is also required in younger women the best choice is
a combined oral contraceptive (<a title=" Combined oral contraceptives" href="4552.htm#_4552">section 7.3.1</a>).</p><p>Progestogens have also been advocated for the alleviation of premenstrual symptoms,
but no convincing physiological basis for such treatment has been
shown.</p><p>Progestogens have been used for the prevention of miscarriage
in women with a history of recurrent miscarriage but there
is no evidence of benefit and they are <b>not</b> recommended
for this purpose. In pregnant women with antiphospholipid antibody
syndrome who have suffered recurrent miscarriage, administration of
low-dose <span>aspirin</span> (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) and a prophylactic dose of a low
molecular weight <span>heparin</span> (<a title="sub-section: Parenteral anticoagulants" href="2761.htm#_2761">section 2.8.1</a>) may decrease the risk of fetal
loss (use under specialist supervision only).</p><div class="cAZ"><h2>Hormone replacement therapy</h2> <p class="cAX">In women with a uterus a progestogen
needs to be added to long-term oestrogen therapy for hormone replacement,
to prevent cystic hyperplasia of the endometrium and possible transformation
to cancer; it can be added on a cyclical or a continuous basis (<a title="topic: Hormone replacement therapy" href="100039.htm#_100039">see section 6.4.1.1</a>). Combined packs incorporating
suitable progestogen tablets are available, see <a title="preparation-group: Conjugated oestrogens with progestogen" href="4325.htm#_4325">Oestrogens for HRT</a>.</p></div><div class="cAZ"><h2>Oral contraception</h2> <p class="cAX">Desogestrel, etynodiol (ethynodiol),
gestodene, levonorgestrel, <span>norethisterone</span>, and
norgestimate are used in combined oral contraceptives and in progestogen-only
contraceptives (<a title=" Combined oral contraceptives" href="4552.htm#_4552">section 7.3.1</a> and <a title=" Progestogen-only contraceptives" href="4571.htm#_4571">section 7.3.2</a>).</p></div><div class="cAZ"><h2>Cancer</h2> <p class="cAX">Progestogens also have a role in neoplastic
disease (<a title=" Progestogens" href="4805.htm#_4805">section
8.3.2</a>).</p></div><div id="_4336.2"><div class="cAZ"><h2>Cautions</h2> <p class="cAX">Progestogens should be used with caution
in conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, and in those
susceptible to thromboembolism (particular caution with high dose). Care is also required in those with a history of depression. Progestogens can decrease glucose
tolerance and patients with diabetes should be monitored
closely. For <b>interactions</b> see Appendix
1 (progestogens).</p></div></div><div id="_4336.1"><div class="cAZ"><h2>Contra-indications</h2> <p class="cAX">Progestogens should be avoided
in patients with a history of liver tumours. They are also contra-indicated in those with genital
or breast cancer (unless progestogens are being used in the management
of these conditions), severe arterial disease, undiagnosed vaginal bleeding and acute porphyria (<a title="sub-section: Acute porphyrias" href="5181.htm#_5181">section 9.8.2</a>). Progestogens should not be
used if there is a history during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis.</p></div></div><div class="cAZ"><h2>Side-effects</h2> <p class="cAX">Side-effects of progestogens include
menstrual disturbances, premenstrual-like syndrome (including bloating,
fluid retention, breast tenderness), weight change, nausea, headache,
dizziness, insomnia, drowsiness, depression, change in libido; also
skin reactions (including urticaria, pruritus, rash, and acne), hirsutism
and alopecia. Jaundice and anaphylactoid reactions have also been
reported.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="201030.htm" title="DYDROGESTERONE">DYDROGESTERONE</a></li><li id="_4347"><a href="4347.htm" title="MEDROXYPROGESTERONE ACETATE">MEDROXYPROGESTERONE ACETATE</a></li><li id="_4350"><a href="4350.htm" title="NORETHISTERONE">NORETHISTERONE</a></li><li id="_4357"><a href="4357.htm" title="PROGESTERONE">PROGESTERONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="73961.htm">Previous: RALOXIFENE HYDROCHLORIDE</a> | <a class="top" href="4336.htm#">Top</a> | <a accesskey="]" href="201030.htm">Next: DYDROGESTERONE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>